Pharmacologic weight management and GLP-1-based therapies: Pharmacologic weight management using GLP-1 receptor agonists and dual incretin agonists represents an emerging preventive strategy for knee osteoarthritis, particularly among individuals with obesity. The gene discussed is GLP1R; the disease is obesity disorder.